NANJING, China, April 1, 2008 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced its participation in Brean Murray, Carret & Co.'s Fourth Investor Tour of China being held from Monday, March 31, 2008 to Friday, April 4, 2008 in Beijing, Shenzhen and Shanghai.
Simcere's Chief Financial Officer Frank Zhao, will present in the Aries Boardroom of the Grand Hyatt Shanghai on Friday April 4, 2008 at 11:15 am Beijing/Hong Kong time.
A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading
manufacturer and supplier of branded generic pharmaceuticals and
manufacturer of the patented anti-cancer biotech product Endu in the
rapidly growing China market. In recent years, Simcere has focused its
strategy on the development of first- to-market generic and innovative
pharmaceuticals, and has introduced a first- to-market generic stroke
management medication under the brand name Bicun and an innovative
anti-cancer medication under the brand name Endu. Simcere currently
manufactures and sells more than 50 pharmaceutical products including
antibiotics, anti-cancer medication and stroke management medication, and
is the exclusive distributor of three additional pharmaceuticals that are
marketed under its brand names. Simcere concentrates its research and
development efforts on the treatment of diseases with high incidence and/or
mortality rates and for which there is a clear demand for more effective
pharmacotherapy such as cancer, strokes, osteoporosis and infectious
diseases, and currently has more than 12 pipeline products. For more
information about Simcere Pharmaceutical Group, please visit
For investor and media inquiries, please contact:
Chief Financial Officer
Tel: +86-25-8556-6666 x8818
In Hong Kong:
In the United States:
Brunswick Group LLC
|SOURCE Simcere Pharmaceutical Group|
Copyright©2008 PR Newswire.
All rights reserved